Name (Synonyms) | Correlation | |
---|---|---|
drug568 | COVID-19 swap test PCR Wiki | 0.71 |
drug380 | Baricitinib or Anakinra Wiki | 0.71 |
drug611 | Cannabis, Medical Wiki | 0.71 |
drug922 | Doxycycline Wiki | 0.35 |
drug2122 | Placebo Wiki | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
D000070627 | Chronic Traumatic Encephalopathy NIH | 0.71 |
D000690 | Amyotrophic Lateral Sclerosis NIH | 0.71 |
D016472 | Motor Neuron Disease NIH | 0.71 |
D005879 | Tourette Syndrome NIH | 0.71 |
D004827 | Epilepsy NIH | 0.71 |
D000755 | Anemia, Sickle Cell NIH | 0.50 |
D003072 | Cognition Disorders NIH | 0.50 |
D001714 | Bipolar Disorder NIH | 0.50 |
D005356 | Fibromyalgia NIH | 0.41 |
D009422 | Nervous System Diseases NIH | 0.41 |
D001927 | Brain Diseases NIH | 0.35 |
D010300 | Parkinsonian NIH | 0.35 |
D003424 | Crohn Disease NIH | 0.32 |
D000070642 | Brain Injuries, Traumatic NIH | 0.27 |
D015212 | Inflammatory Bowel Diseases NIH | 0.27 |
D059350 | Chronic Pain NIH | 0.25 |
D001930 | Brain Injuries, NIH | 0.24 |
D060825 | Cognitive Dysfunction NIH | 0.22 |
D012598 | Scoliosi NIH | 0.21 |
D009103 | Multiple Sclerosis NIH | 0.20 |
D020521 | Stroke NIH | 0.20 |
D040921 | Stress Disorders, Traumatic NIH | 0.14 |
D014947 | Wounds and Injuries NIH | 0.14 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.13 |
D004194 | Disease NIH | 0.12 |
D013577 | Syndrome NIH | 0.07 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001250 | Seizure HPO | 0.82 |
HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.71 |
HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.71 |
HP:0100754 | Mania HPO | 0.50 |
HP:0001298 | Encephalopathy HPO | 0.35 |
HP:0100280 | Crohn's disease HPO | 0.32 |
HP:0002037 | Inflammation of the large intestine HPO | 0.27 |
HP:0012532 | Chronic pain HPO | 0.25 |
HP:0001268 | Mental deterioration HPO | 0.22 |
HP:0001297 | Stroke HPO | 0.20 |
There are 2 clinical trials
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsThe purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsDescription: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 months